Braveheart Bio

Company Deals

Hengrui Licenses HRS‑1893 to Braveheart Bio in $75 M Deal – Global Myosin Inhibitor

Fineline Cube Sep 5, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing arrangement with...

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod